PMID- 38430414
OWN - NLM
STAT- MEDLINE
DCOM- 20240411
LR  - 20240416
IS  - 1568-5608 (Electronic)
IS  - 0925-4692 (Linking)
VI  - 32
IP  - 2
DP  - 2024 Apr
TI  - Sinomenine protects against atherosclerosis in apolipoprotein E-knockout mice by 
      inhibiting of inflammatory pathway.
PG  - 1387-1400
LID - 10.1007/s10787-024-01437-8 [doi]
AB  - Atherosclerosis, a multifaceted and persistent inflammatory condition, 
      significantly contributes to the progression of cardiocerebrovascular disorders, 
      such as myocardial infarctions and cerebrovascular accidents. It involves the 
      accumulation of cholesterol, fatty deposits, calcium and cellular debris in the 
      walls of arteries, leading to the formation of plaques. Our aim is to investigate 
      the potential of sinomenine to counteract atherosclerosis in mice lacking 
      Apolipoprotein E (ApoE-/-) Mice. We employed the high-fat diet-induced method to 
      induce atherosclerosis in ApoE-/- mice, and the mice were treated with sinomenine 
      (5, 10, and 15 mg/kg) and simvastatin (0.5 mg/kg) for 12 weeks. Body weight, 
      water intake, and food intake were assessed. Lipid parameters, oxidative stress, 
      inflammatory cytokines, and mRNA levels were estimated. Sinomenine treatment 
      remarkably (P < 0.001) suppressed body weight, along with food and water intake. 
      Sinomenine altered the levels of total cholesterol (TC), high-density lipoprotein 
      (HDL), triglyceride (TG), low-density lipoprotein (LDL), and very low-density 
      lipoprotein (VLDL), which were modulated in the atherosclerosis group. Sinomenine 
      treatment also altered the levels of oxidative stress parameters such as 
      glutathione peroxidase (GPx), catalase (CAT), malonaldehyde (MDA), superoxide 
      dismutase (SOD) and glutathione (GSH). In addition, it modulated cardiac 
      parameters like C-reactive protein (CRP), endothelin-1 (ET-1), thromboxane B2 
      (TXB2), nitric oxide (NO), cardiac troponin I (cTnI), lactate dehydrogenase 
      (LDH), and creatinine kinase isoenzymes (CK-MB). Inflammatory cytokines 
      interleukin (IL)-1alpha, IL-1beta, TNF-alpha, IL-6, and IL-10 were also affected. Sinomenine 
      further suppressed the mRNA expression of IL-6, IL-17, IL-10, tumor necrosis 
      factor-alpha (TNF-alpha), Il-1beta, monocyte chemoattractant protein-1 (MCP-1), MCP-2, 
      MCP-3, transforming Growth Factor-1beta (TGF-1beta), vascular cell adhesion molecule 1 
      (VCAM-1), and intercellular adhesion molecule-1 (ICAM-1). The results suggest 
      that sinomenine remarkably suppressed the development of atherosclerosis in the 
      early stage.
CI  - (c) 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
FAU - Gao, Zhao
AU  - Gao Z
AD  - Department of Cardiology, Xi'an International Medical Center Hospital, Xi'an, 
      710100, China.
FAU - Yang, Chao
AU  - Yang C
AD  - Department of Nephrology, Shaanxi Provincial Corps Hospital of Chinese People's 
      Armed Police Force, Xi'an, 710054, China.
FAU - Zeng, Guangwei
AU  - Zeng G
AD  - Department of Cardiology, Xi'an International Medical Center Hospital, Xi'an, 
      710100, China.
FAU - Lin, Ming
AU  - Lin M
AD  - Akshita College of Pharmacy, Meerut, India.
FAU - Li, Wei
AU  - Li W
AD  - Department of Cardiology, Xi'an International Medical Center Hospital, Xi'an, 
      710100, China.
FAU - Sun, Mengna
AU  - Sun M
AD  - Department of Cardiology, Xi'an International Medical Center Hospital, Xi'an, 
      710100, China.
FAU - Zhang, Yantao
AU  - Zhang Y
AD  - Department of Cardiology, Xi'an International Medical Center Hospital, Xi'an, 
      710100, China.
FAU - Fan, Beibei
AU  - Fan B
AD  - Department of Cardiology, Xi'an International Medical Center Hospital, Xi'an, 
      710100, China.
FAU - Kumar, Yogesh
AU  - Kumar Y
AD  - Akshita College of Pharmacy, Meerut, India.
FAU - Yan, Kun
AU  - Yan K
AUID- ORCID: 0009-0009-7410-8165
AD  - Department of Outpatient, Shaanxi Provincial Corps Hospital of Chinese People's 
      Armed Police Force, Xi'an, 710054, China. wjyankun@outlook.com.
LA  - eng
PT  - Journal Article
DEP - 20240302
PL  - Switzerland
TA  - Inflammopharmacology
JT  - Inflammopharmacology
JID - 9112626
RN  - 0 (Apolipoproteins)
RN  - 0 (Apolipoproteins E)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - 0 (Cytokines)
RN  - 130068-27-8 (Interleukin-10)
RN  - 0 (Interleukin-6)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Morphinans)
RN  - 0 (RNA, Messenger)
RN  - 63LT81K70N (sinomenine)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Animals
MH  - Mice
MH  - Apolipoproteins
MH  - Apolipoproteins E
MH  - *Atherosclerosis/drug therapy/metabolism
MH  - Body Weight
MH  - Cholesterol
MH  - Cytokines
MH  - *Interleukin-10
MH  - Interleukin-6
MH  - Lipoproteins, LDL
MH  - Mice, Knockout
MH  - Mice, Knockout, ApoE
MH  - *Morphinans
MH  - RNA, Messenger
MH  - Tumor Necrosis Factor-alpha/metabolism
OTO - NOTNLM
OT  - Atherosclerosis
OT  - Inflammatory cytokines
OT  - MCP
OT  - Oxidative stress
OT  - Sinomenine
EDAT- 2024/03/02 12:48
MHDA- 2024/04/11 06:43
CRDT- 2024/03/02 11:15
PHST- 2023/10/15 00:00 [received]
PHST- 2024/01/15 00:00 [accepted]
PHST- 2024/04/11 06:43 [medline]
PHST- 2024/03/02 12:48 [pubmed]
PHST- 2024/03/02 11:15 [entrez]
AID - 10.1007/s10787-024-01437-8 [pii]
AID - 10.1007/s10787-024-01437-8 [doi]
PST - ppublish
SO  - Inflammopharmacology. 2024 Apr;32(2):1387-1400. doi: 10.1007/s10787-024-01437-8. 
      Epub 2024 Mar 2.